# Avicanna Inc. Sponsors University of Calgary THC Dose Finding Clinical Trial > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/thc-dose-finding-clinical-trial-avicanna-sponsorship/ > **Published:** 2026-03-16T12:52:13-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:06:52-04:00 > **Clinical Summary:** Avicanna sponsors a THC dose finding clinical trial at University of Calgary to establish evidence-based THC dosing guidelines for safer cannabis use. --- ✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchDosingTHCSafety[Clinical Trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) Why This Matters This Phase I dose-finding trial addresses a critical gap in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) by establishing evidence-based THC dosing guidelines, which clinicians currently lack when treating patients. Standardized dosing data from rigorous clinical trials enables more precise prescribing practices that can optimize therapeutic outcomes while minimizing adverse effects and [cannabinoid hyperemesis](https://cedclinic.com/cannabis-hyperemesis-syndrome-virginia-er-cases-surge/) syndrome risk. As regulatory bodies increasingly require clinical evidence to support cannabis-based product approvals, this research directly supports the development of pharmaceutical-grade cannabis medications that meet the safety and efficacy standards patients and clinicians expect from conventional drugs. Clinical Summary Avicanna Inc. is sponsoring a Phase I randomized, double-blinded, placebo-controlled dose-finding trial at the University of Calgary to establish optimal tetrahydrocannabinol (THC) dosing parameters in a controlled clinical setting. This type of foundational pharmacokinetic and safety research is essential for developing evidence-based dosing guidelines that clinicians can rely upon when recommending cannabis products to patients, as current clinical practice often lacks rigorous dose-response data. The double-blinded, placebo-controlled design strengthens the scientific credibility of findings by reducing bias and clearly attributing outcomes to the active compound rather than expectancy effects. Results from this trial may inform standardized dosing recommendations across different patient populations and clinical indications, moving cannabis therapeutics closer to the evidence standards applied to conventional pharmaceuticals. Clinicians should monitor publication of this trial’s findings as they emerge, as validated dosing information will improve their ability to counsel patients on appropriate THC exposure and minimize adverse effects while optimizing therapeutic benefit. Dr. Caplan’s Take “What we’re seeing with industry-sponsored dose-finding studies is finally the kind of rigorous pharmacokinetic work that should have been done decades ago, and while we need to remain vigilant about conflicts of interest, this particular trial design gives us the methodological foundation to move beyond anecdotal dosing and toward evidence-based THC protocols that will actually serve our patients better in clinical practice.” Clinical Perspective While industry-sponsored [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) can accelerate our understanding of THC dosing and safety parameters, clinicians should recognize that manufacturer funding may introduce bias in study design, publication, and interpretation of results. Dose-finding trials are methodologically important for establishing pharmacokinetic profiles and adverse event thresholds, yet the commercial interest in identifying marketable THC formulations may influence which populations are studied, which endpoints are prioritized, and how findings are ultimately disseminated. The double-blind, placebo-controlled design is a strength, but clinicians should await peer-reviewed publication in independent journals and look for transparent reporting of any conflicts of interest before incorporating findings into practice recommendations. Until such results are published and independently verified, current evidence-based guidance on THC dosing remains limited, and prescribers should continue to emphasize individualized, conservative titration strategies with patients given the heterogeneity of THC sensitivity and potential for adverse 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Avicanna+Inc.+Announces+Sponsorship+of+University+of+Calgary+THC+Dose+Finding+Clinical+Trial+%40drcaplan&url=https%3A%2F%2Fwww.marketscreener.com%2Fnews%2Favicanna-inc-announces-sponsorship-of-university-of-calgary-thc-dose-finding-clinical-trial-ce7e5edadc8df123)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.marketscreener.com%2Fnews%2Favicanna-inc-announces-sponsorship-of-university-of-calgary-thc-dose-finding-clinical-trial-ce7e5edadc8df123)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Avicanna+Inc.+Announces+Sponsorship+of+University+of+Calgary+THC+Dose+Finding+Clinical+Trial+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.marketscreener.com%2Fnews%2Favicanna-inc-announces-sponsorship-of-university-of-calgary-thc-dose-finding-clinical-trial-ce7e5edadc8df123)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Avicanna Announces Sponsorship of University of Calgary THC Dose Finding Clinical Trial](https://cedclinic.com/thc-dosing-clinical-trial-avicanna-sponsorship/) - [This Week in Cannabis: March 16, 2026](https://cedclinic.com/cannabis-clinical-research-therapeutic-applications-march-2026/) - [AM News Update: March 16, 2026](https://cedclinic.com/cannabis-use-by-older-adults-mental-decline-2026/) 📰 Source: [https://www.marketscreener.com/news/avicanna-inc-announces-sponsorship-of-university-of-calgary-thc-dose-finding-clinical-trial-ce7e5edadc8df123](https://www.marketscreener.com/news/avicanna-inc-announces-sponsorship-of-university-of-calgary-thc-dose-finding-clinical-trial-ce7e5edadc8df123) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Avicanna Backs University of Calgary Trial to Map Optimal Oral THC Dosing – TipRanks.com](https://cedclinic.com/oral-thc-dosing-anxiety-clinical-trial/) Explore how Avicanna supports [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) to determine optimal oral THC dosing for improved patient outcomes. [Read More](https://cedclinic.com/oral-thc-dosing-anxiety-clinical-trial/) [Avicanna announces sponsorship of University of Calgary THC dose finding clinical trial](https://cedclinic.com/thc-dosing-clinical-trial-avicanna-sponsorship/) Details on Avicanna's sponsorship of a key clinical trial aiming to establish standardized THC dosing protocols. [Learn More](https://cedclinic.com/thc-dosing-clinical-trial-avicanna-sponsorship/) [Avicanna Sponsoring THC Dose Finding Clinical Trial at University of Calgary](https://cedclinic.com/thc-dosing-anxiety-clinical-trial-avicanna/) Insights into the clinical trial sponsored by Avicanna focused on THC dose finding to enhance cannabis therapeutics. [Discover More](https://cedclinic.com/thc-dosing-anxiety-clinical-trial-avicanna/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).